A new test to predict colon cancer risk in people with genetic predispositions.
Robust Predictor of Colon Cancer Risk
This study is working on a quick and affordable blood test to help find people at high risk for colon cancer because of Lynch syndrome, a genetic condition that many don’t know they have, so they can get better prevention and care.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Morgan and Mendel Genomics, INC. NIH-funded |
| Lab location | 1 site (Wilmington, United States) |
| Project ID | NIH-10684777 on NIH RePORTER |
What this research studies
This research focuses on developing a rapid and cost-effective test to identify individuals at high risk for colon cancer due to Lynch syndrome, a genetic condition linked to mutations in the mismatch repair pathway. Many people with Lynch syndrome are unaware of their condition, often due to uninformative family histories. The study aims to create a flow variant assay (FVA) that can detect molecular changes in blood cells, providing a reliable alternative to traditional genetic testing. This test will help classify cancer risk more accurately and could lead to better prevention strategies for those at risk.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with a family history of Lynch syndrome or those who are at high risk for colon cancer but have not received a definitive genetic diagnosis.
Not a fit: Patients without a genetic predisposition to Lynch syndrome or those who do not have a family history of related cancers may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a straightforward method for identifying individuals at high risk for colon cancer, enabling earlier interventions and personalized treatment plans.
How similar studies have performed: Other research has shown promise in using flow variant assays for similar genetic risk assessments, indicating that this approach could be effective.
Where this research is happening
Wilmington, United States
- Morgan and Mendel Genomics, INC. — Wilmington, United States (Active)
Researchers
- Principal investigator: Ostrer, Harry — Morgan and Mendel Genomics, INC.
- Study coordinator: Ostrer, Harry
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.